Brokerages Set Cellectis S.A. (NASDAQ:CLLS) Target Price at $7.00

Cellectis S.A. (NASDAQ:CLLS) has earned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $7.00.

CLLS has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. Barclays initiated coverage on Cellectis in a research note on Thursday, May 28th. They set an “overweight” rating and a $9.00 target price on the stock.

Institutional Trading of Cellectis

Several hedge funds have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Cellectis during the 4th quarter valued at approximately $15,385,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after purchasing an additional 3,284,409 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after purchasing an additional 168,038 shares during the period. Citadel Advisors LLC bought a new stake in shares of Cellectis in the 3rd quarter worth approximately $633,000. Finally, Millennium Management LLC lifted its stake in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the last quarter. Institutional investors own 63.90% of the company’s stock.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $3.11 on Tuesday. Cellectis has a twelve month low of $2.35 and a twelve month high of $5.48. The stock’s 50 day moving average price is $2.93 and its 200-day moving average price is $3.42. The company has a market capitalization of $312.06 million, a PE ratio of -4.78 and a beta of 2.91. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.04. The company had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.